Compare Chart Industries Inc (GTLS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chart Industries Inc vs Smith & Nephew plc — how do they compare? Chart Industries Inc trades at $209.97 (market cap $10.05B), while Smith & Nephew plc trades at $31.3 (market cap $12.81B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.54% dividend while Chart Industries Inc pays none. Which is the better fit depends on your goals.
| GTLS | SNN | |
|---|---|---|
Market Cap | $10.05B | $12.81B |
Sector | Technology | Health |
52-Week High | $209.91 | $38.70 |
52-Week Low | $167.29 | $28.73 |
Enterprise Value | $13.57B | $15.58B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GTLS trades at $209.97, up 0.03% on the day, with a bullish technical signal driven by moving averages. The company reported $4.26B revenue for 2025 but missed earnings estimates for three consecutive quarters, with a net income margin of -0.62%. Recent news highlights Baker Hughes' pending $13.6B acquisition, which received conditional EU approval in July 2026.
The outlook is mixed: strong analyst support (54% buy ratings) and acquisition potential offer upside, but weak profitability and earnings misses pose risks. Investors should weigh the acquisition's completion against fundamental challenges in the near term.
Smith & Nephew (SNN) trades at $31.41, up 5.28% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $5.8B in 2024 to $6.2B projected for 2025 and net income margin expanding to 10.14%. Recent product launches in robotics and wound care, plus a $500M share buyback, highlight strategic execution. Analyst consensus is mixed with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility where two of the last four quarters missed expectations.
Outlook: SNN's recovery trajectory and product innovation support long-term growth, but investor patience is needed due to earnings inconsistency and moderate debt levels. Key risks include competitive pressures in medtech and execution on guidance. The stock presents a value opportunity if operational improvements continue, trading at reasonable valuations (P/E 21.5, P/S 2.18) versus sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chart Industries Inc
Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
